Abstract
Currently, the world is facing the pandemic of a novel strain of beta-coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Acute respiratory distress syndrome (ARDS) is the most devastating complication of SARS-CoV-2. It was indicated that cytokine-release syndrome and dominantly interleukin (IL)-6 play a central role in the pathophysiology of ARDS related to the novel 2019 coronavirus disease (COVID-19). Despite the global emergency of the disease, at this time, there are no proven therapies for the management of the disease. Tocilizumab is a potential recombinant monoclonal antibody against IL-6 and currently is under investigation for the management of ARDS in patients with COVID-19. Given these points, we reviewed the current evidence regarding the potential therapeutic role of tocilizumab and its important clinical issues in the treatment of ARDS related to COVID-19.
Keywords: ARDS; COVID-19; CRS; IL-6; SARS-CoV-2; acute lung injury; tocilizumab.
【저자키워드】 COVID-19, SARS-CoV-2, ARDS, IL-6, acute lung injury, tocilizumab., CRS, 【초록키워드】 Treatment, coronavirus, pandemic, therapy, Tocilizumab, monoclonal antibody, lung, cytokine-release syndrome, pathophysiology, management, therapeutic, 2019 coronavirus disease, Evidence, distress, beta-coronavirus, acute respiratory syndrome, syndrome, indicated, the disease, patients with COVID-19, 【제목키워드】 review, respiratory, Comprehensive,